Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 199

Similar articles for PubMed (Select 23185117)

1.

Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats.

Yang X, Chen Y, Hong X, Wu N, Song L, Yuan W, Liu Z.

Drug Des Devel Ther. 2012;6:341-7. doi: 10.2147/DDDT.S38008. Epub 2012 Nov 20.

2.

Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats.

Yang X, Zheng R, Cai Y, Liao M, Yuan W, Liu Z.

Int J Nanomedicine. 2012;7:2077-86. doi: 10.2147/IJN.S30463. Epub 2012 Apr 19.

3.

Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats.

Ren T, Yang X, Wu N, Cai Y, Liu Z, Yuan W.

Neurosci Lett. 2011 Sep 15;502(2):117-22. doi: 10.1016/j.neulet.2011.07.042. Epub 2011 Aug 4.

PMID:
21835223
4.

Levodopa/benserazide-loaded biodegradable microspheres reduce dyskinesia in rats.

Yang X, Yuan W, Ren T, Song L, Wu N, Liu Z.

Neuroreport. 2010 Aug 23;21(12):837-40. doi: 10.1097/WNR.0b013e32833d40c8.

PMID:
20631586
5.

Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.

Kobylecki C, Crossman AR, Ravenscroft P.

Exp Neurol. 2013 Sep;247:476-84. doi: 10.1016/j.expneurol.2013.01.019. Epub 2013 Jan 27.

PMID:
23360800
6.

Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.

Kobylecki C, Cenci MA, Crossman AR, Ravenscroft P.

J Neurochem. 2010 Jul;114(2):499-511. doi: 10.1111/j.1471-4159.2010.06776.x. Epub 2010 Apr 28.

PMID:
20456008
7.
8.

5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.

Tronci E, Lisci C, Stancampiano R, Fidalgo C, Collu M, Devoto P, Carta M.

Neurobiol Dis. 2013 Dec;60:108-14. doi: 10.1016/j.nbd.2013.08.014. Epub 2013 Sep 1.

PMID:
24004632
9.

The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.

Yin LL, Geng XC, Zhu XZ.

Brain Res Bull. 2011 Nov 25;86(5-6):367-72. doi: 10.1016/j.brainresbull.2011.09.016. Epub 2011 Sep 24.

PMID:
21963945
10.

Intrastriatal injections of KN-93 ameliorates levodopa-induced dyskinesia in a rat model of Parkinson's disease.

Yang X, Wu N, Song L, Liu Z.

Neuropsychiatr Dis Treat. 2013;9:1213-20. doi: 10.2147/NDT.S45422. Epub 2013 Aug 19.

11.

Ranitidine reduced levodopa-induced dyskinesia in a rat model of Parkinson's disease.

Cui G, Yang X, Wang X, Zhang Z, Yue X, Shi H, Shen X.

Neuropsychiatr Dis Treat. 2014;10:39-46. doi: 10.2147/NDT.S54782. Epub 2013 Dec 18.

12.

RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.

Ko WK, Martin-Negrier ML, Bezard E, Crossman AR, Ravenscroft P.

Neurobiol Dis. 2014 Oct;70:138-48. doi: 10.1016/j.nbd.2014.06.013. Epub 2014 Jun 24.

PMID:
24969021
13.

Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.

Tronci E, Fidalgo C, Zianni E, Collu M, Stancampiano R, Morelli M, Gardoni F, Carta M.

Neuroscience. 2014 Apr 18;265:245-52. doi: 10.1016/j.neuroscience.2014.01.042. Epub 2014 Jan 30.

PMID:
24486947
14.

Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.

Fiorentini C, Savoia P, Savoldi D, Barbon A, Missale C.

Neurobiol Dis. 2013 Jun;54:339-48. doi: 10.1016/j.nbd.2013.01.005. Epub 2013 Jan 14.

PMID:
23328768
15.

The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms.

Gerlach M, Halley P, Riederer P, van den Buuse M.

J Neural Transm. 2013 Jan;120(1):31-6. doi: 10.1007/s00702-012-0818-7. Epub 2012 May 17.

PMID:
22592937
16.
17.

Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease.

Putterman DB, Munhall AC, Kozell LB, Belknap JK, Johnson SW.

J Pharmacol Exp Ther. 2007 Oct;323(1):277-84. Epub 2007 Jul 27.

18.

An autoradiographic study on the pathogenesis of levodopa-induced dyskinesia: regulation of dopamine transporter by levodopa in a rat model of Parkinson's disease.

Cai XY, Kong XM, Fang Q, Ning P, Xu YJ, Zhang B, Xue SR.

Neurodegener Dis. 2012;9(1):11-7. doi: 10.1159/000328816. Epub 2011 Aug 26.

PMID:
21876323
19.

Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat.

Lindenbach D, Ostock CY, Eskow Jaunarajs KL, Dupre KB, Barnum CJ, Bhide N, Bishop C.

J Pharmacol Exp Ther. 2011 Jun;337(3):755-65. doi: 10.1124/jpet.111.179416. Epub 2011 Mar 14.

20.

Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.

Visanji NP, Fox SH, Johnston T, Reyes G, Millan MJ, Brotchie JM.

Neurobiol Dis. 2009 Aug;35(2):184-92. doi: 10.1016/j.nbd.2008.11.010. Epub 2008 Dec 9.

PMID:
19118628
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk